Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.38% | 10.98% | 58.13% | 625.83% | -96.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.38% | 10.98% | 58.13% | 625.83% | -96.74% |
| Cost of Revenue | -9.34% | 4.46% | 1.09% | -15.34% | -51.03% |
| Gross Profit | 8.96% | -3.72% | 2.34% | 30.32% | -354.40% |
| SG&A Expenses | -33.96% | -4.83% | 9.78% | -23.74% | -4.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.03% | -1.77% | 4.19% | -18.34% | -39.49% |
| Operating Income | 19.17% | 2.21% | -2.14% | 27.94% | -78.61% |
| Income Before Tax | 21.63% | -18.20% | -5.55% | 27.16% | -154.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.63% | -18.20% | -5.55% | 27.16% | -154.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.63% | -18.20% | -5.55% | 27.16% | -154.25% |
| EBIT | 19.17% | 2.21% | -2.14% | 27.94% | -78.61% |
| EBITDA | 17.95% | 2.30% | -2.65% | 30.53% | -89.53% |
| EPS Basic | 33.07% | 1.05% | 11.67% | 38.99% | -146.52% |
| Normalized Basic EPS | 33.06% | 36.38% | 11.66% | 44.06% | -146.63% |
| EPS Diluted | 33.07% | 1.05% | 11.67% | 38.99% | -146.52% |
| Normalized Diluted EPS | 33.06% | 36.38% | 11.66% | 44.06% | -146.63% |
| Average Basic Shares Outstanding | 17.08% | 19.45% | 19.48% | 19.38% | 3.11% |
| Average Diluted Shares Outstanding | 17.08% | 19.45% | 19.48% | 19.38% | 3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |